Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just released highlights from its DIAB-A22-1 animal study on rodents. The study sought to explore the overall efficiency of its patented DehydraTECH(TM)-CBD formulation and its impact on conditions associated … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced that the U.S. Food and Drug Administration (“FDA”) has given it the requisite clearance to proceed with its planned U.S. Phase 1b hypertension clinical trial. This follows … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has appointed a new chief financial officer. The company announced that, effective immediately, Nelson Cabatuan, CPA, will serve in the position, which also entails being a member of Lexaria’s … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, has been pushing the envelope and redefining drug delivery technology. Its patented DehydraTECH(TM) technology has proven itself in numerous studies since 2016, highlighting its ability to increase bio-absorption compared … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to perform the company’s second DehydraTECH-powered glucagon-like peptide 1 (“GLP-1”) human pilot study #2. According to the announcement, … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced details for an eight-week animal study, WEIGHT-A24-1, to examine diabetes and weight loss effects of DehydraTECH-processed glucagon-like peptide 1 (“GLP-1”) drugs and DehydraTECH-processed cannabidiol, alone and … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is reporting glucose reduction and weight-loss results in a testing of its wholly owned and patented DehydraTECH-CBD formulation. According to the announcement, when administered to rodents in an eight-week … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that the U.S. Food and Drug Administration (“FDA”) has confirmed the effectiveness of the company’s investigational new drug (“IND”) application thereby clearing Lexaria to conduct its … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced that the registered direct offering for the purchase and sale of 1,558,443 shares of common stock at a purchase price of $2.31 – at the market under … Continue reading →

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, has closed on a registered direct offering. The offering included the purchase and sale of 1,558,443 shares of common stock (or common stock equivalents in lieu thereof) offered at … Continue reading →